HK-listed Antengene at 2-1/2-year peak on Xpovio approval in China

Antengene

29/07/2025 03:55

** Shares of Antengene Corp 6996.HK rise 5.6% to HK$5.84

** Stock at highest level since Feb 2023, set for sixth consecutive session of gains

** Innovative oncology medicines-focused clinical-stage biopharmaceutical group says its Xpovio approved in China for second-line treatment of multiple myeloma

** Hang Seng Biotech Index .HSHKBIO rises 2.6%, while benchmark Hang Seng Index .HSI falls 1.1%

** YTD, stock up 783%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))